Company news
Firebrick Pharma Limited news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Agreement Signed to Market Nasodine to HCPs in Singapore
October 30, 2024
September 2024 Quarterly Activity Report & Appendix 4C
October 22, 2024
Completion of Share Purchase Plan
October 9, 2024
Firebrick receives $0.9 million R&D Tax Incentive
September 22, 2024
Share Purchase Plan
September 11, 2024
Appendix 4E and Annual Report 30 June 2024
August 30, 2024
New agreement allows Nasodine launch in Philippines
August 14, 2024
June 2024 Quarterly Activity Report & Appendix 4C
July 29, 2024
Firebrick Launches Nasodine in Singapore
June 12, 2024
Firebrick Raises $800,000 via Placement
May 16, 2024
March 2024 Quarterly Activity Report & Appendix 4C
April 22, 2024
Nasodine Nasal Spray Launch in the USA
April 16, 2024
Appendix 4D & Half-Year Financial Report to 31 December 2023
February 28, 2024
December 2023 Quarterly Activity Report & Appendix 4C
January 23, 2024
Firebrick Investor Update
November 14, 2023
Firebrick Receives $1.81m R&D Tax Incentive
October 30, 2023
September 2023 Quarterly Activity Report & Appendix 4C
October 26, 2023
Update on Nasodine Trial and Forward Plans
October 2, 2023
Phase 3 Common Cold Trial Results
September 13, 2023
Appendix 4E & Annual Report FY23
August 29, 2023
Response to ASX Price and Volume Query
August 28, 2023
Firebrick Phase 3 Trial Closes with 500 Subjects
August 8, 2023
Firebrick Covid-19 Trial Achieves Primary Endpoint
August 6, 2023
June 2023 Quarterly Activity Report & Appendix 4C
July 26, 2023
Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment
May 30, 2023
Firebrick Raises $1 million via Placement
April 30, 2023
March 2023 Quarterly Activity Report & Appendix 4C
April 19, 2023
Nasodine COVID-19 Trial Concludes Recruitment
April 3, 2023
Firebrick Pharmas Phase 3 Trial of Nasodine Resumes
March 20, 2023
FRE files EU Paediatric Investigation Plan for Nasodine
February 20, 2023
Appendix 4D & Half Yearly Report and Accounts
February 17, 2023
December 2022 Quarterly Activity Report & Appendix 4C
January 18, 2023
Nasodine Composition Patent Accepted in Australia
November 13, 2022
Firebrick Receives $1.08m R&D Tax Incentive
November 8, 2022
September 2022 Quarterly Activity Report & Appendix 4C
October 31, 2022
Appendix 4E & Annual Report
August 23, 2022
June 2022 Quarterly Activity Report & Appendix 4C
July 28, 2022
Outcome of s60 appeal for Nasodine and next steps
July 7, 2022
Firebrick starts Phase 3 common cold trial of Nasodine
May 3, 2022
March 2022 Quarterly Activity Report & Appendix 4C
April 26, 2022
Firebrick starts COVID-19 trial of Nasodine
April 26, 2022
31 December Interim Financial Report & Appendix 4D
February 11, 2022
Decks
The 5 newest of 9 decks. Every deck is listed under its year.
- Aussie Equities Day, Singapore 2026
Conference · 15 slides · Oct 7, 2026
- Investor Presentation (March 2026)
Investor deck · 18 slides · Mar 4, 2026
- Shareholder Meeting (November 2025)
Shareholder meeting · 24 slides · Nov 26, 2025
- Investor Presentation (June 2025)
Investor deck · 20 slides · Jun 23, 2025
- Shareholder Meeting (November 2024)
Shareholder meeting · 18 slides · Nov 27, 2024